A collaboration between the BHS MM working group & Janssen-Cilag NV

                                                                                                    

ABOUT MRD Testing

MRD (minimal residual disease) testing is a more sensitive measure compared with traditional definitions of clinical response which helps to detect residual tumor cells in the bone marrow and to better discriminate patients at risk for relapsing accordingly. 

• MRD is an important prognostic factor in multiple myeloma
• MRD is a valuable measure to evaluate therapeutic efficacy in multiple myeloma

MMOVE PROJECT'S GOAL

The goal of treatment in multiple myeloma is achieving deep and durable responses, but MRD is currently not widely measured in Belgium due practical & financial limitations.

MMOVE project aims to make MRD measurement available for multiple myeloma patients in Belgium: 

• Make it possible for all Belgian hematologists to have MRD measured for their patients
• Build experience & create a sustainable network for analysis
• Be ready for the future > When MRD results have consequences in treatment of multiple myeloma

MMOVE PROJECT WORKFLOW

To achieve this goal, the BHS Multiple Myeloma-workgroup initiated a cooperation with Janssen-Cilag NV:

MRD Workflow - UZ Gent	MRD Workflow - UZ Brussel	MRD Workflow - UZ Leuven
MRD Workflow - CHU Liège	Jessa Ziekenhuis Hasselt	CHR de Namur